AN ADVANCED PRACTICE PROVIDER (APP) DRIVEN, WEIGHT INTERVENTION IN LIVER DISEASE (WILD) CLINICAL PATHWAY ACHIEVES MORE MEANING WEIGHT LOSS IN PATIENTS WITH MASLD COMPARED TO STANDARD OR CARE
<div><p><b>Background:</p> </b><p>As the prevalence of obesity and MASH continues to grow, novel treatment options are needed to prevent progression as there are currently no medications approved to treat MASH. Weight loss has been shown to be an effective treatment with a 5% weight loss reversing steatosis and a 10% weight loss reversing liver fibrosis. Clinical trials using lifestyle-based weight loss interventions in MASH have been shown to achieve >5% total body weight loss (TBWL) in 30% of patients and >10% TBWL in 10% of patients.